A security tag can prohibit unauthorized usage of a device or product. The device may include an electronic nicotine delivery systems (“ENDS”) device, which may include aerosol delivery devices such as smoking articles that produce aerosol. The security tag can prevent usage until authorized. Attempts at usage without authorization can result in the device being unusable. The authorization may include identity confirmation or age verification.

A method of controlling or electing the harshness of inhaled nicotine powder formulations is described. The method includes the steps of identifying a concentration of nicotine for a subject to inhale to achieve a desired level of harshness per inhalation, identifying the total dose of nicotine to be inhaled by the subject, and providing the subject with an amount of a formulation comprising nicotine particles having the identified concentration of nicotine, such that the total amount of nicotine particles in the formulation equals the total dose of nicotine.

A method of controlling or electing the harshness of inhaled nicotine powder formulations is described. The method includes the steps of identifying a concentration of nicotine for a subject to inhale to achieve a desired level of harshness per inhalation, identifying the total dose of nicotine to be inhaled by the subject, and providing the subject with an amount of a formulation comprising nicotine particles having the identified concentration of nicotine, such that the total amount of nicotine particles in the formulation equals the total dose of nicotine.

A foam inhalation device (874) for dispensing a foam to be inhaled by a user. The inhalation device (874) comprises a foam-generating component for generating the foam, an outlet (882) for dispensing the foam to the user, and a fluid flow path which fluidly communicates the foam-generating component with the outlet (882). The foam is generatable by the foam-generating component and flows to the outlet (882) via the fluid flow path to be inhaled by the user.

The present invention provides a D-serine transport modifier which is characterized by controlling the transport of D-serine into and out of cells by a D-serine transporter protein, a pharmaceutical composition which comprises the same as an active component and treats or prevents diseases relating to an increase or decrease in the amount of D-serine, and a screening method of substances that control the transport of D-serine. The present invention also provides a screening method of a D-serine transporter protein.

The present invention provides a D-serine transport modifier which is characterized by controlling the transport of D-serine into and out of cells by a D-serine transporter protein, a pharmaceutical composition which comprises the same as an active component and treats or prevents diseases relating to an increase or decrease in the amount of D-serine, and a screening method of substances that control the transport of D-serine. The present invention also provides a screening method of a D-serine transporter protein.

A non-tobacco oral nicotine pouch composition is provided, including water in an amount of at least 15% by weight of the pouch composition; nicotine; and at least one sugar alcohol, the pouch composition being free of humectants consisting of alginate, propylene glycol, hydroxypropyl cellulose, and glycerol. An oral pouched nicotine product is also provided, including a saliva-permeable pouch and the non-tobacco oral nicotine pouch composition enclosed in the saliva-permeable pouch.

The disclosure provides for an oral composition, the oral composition including at least one active agent, at least one filler component, and water in an amount sufficient such that the oral composition has a total moisture content of about 15% to about 30% by weight or greater based on the total weight of the oral composition.

A method for treating or mitigating Parkinson's disease (PD) symptoms or progression, including administering an effective amount of nicotine to a subject in need thereof, via inhalation using a nicotine inhaler or via nasal spray using a nicotine nasal spray. Significant dose-dependent improvement of all symptoms by nicotine inhaler or nicotine nasal spray is expected. A novel treatment in PD is thus provided.

A method for treating or mitigating Parkinson's disease (PD) symptoms or progression, including administering an effective amount of nicotine to a subject in need thereof, via inhalation using a nicotine inhaler or via nasal spray using a nicotine nasal spray. Significant dose-dependent improvement of all symptoms by nicotine inhaler or nicotine nasal spray is expected. A novel treatment in PD is thus provided.